Please Subscribe!

Sunday, 4 March 2012

Cabozantinib

This may be a little late, but this article came to my attention in the 03/03/12 edition of New Scientist (pg 14, 15). It concerns the results of an experimental anti-cancer drug named Cabozantinib, or "Cabo" for short as the publication dubs it:

"Three months into a trial of an experimental anti-cancer drug, scans that should have revealed bones riddled with cancer were coming up almost clean…It [Cabo] blocks a particular receptor on cancer cells called c-MET, which would otherwise help them spread to new tissue…The trial also suggests that as an unexpected bonus, Cabo blocks a tumour's blood supply, which helps it destroy tumours as well as contain them."

It's clear that Cabo seems to be getting rave reviews from scientists, who appear to be heralding Cabo as a potential super-drug. Will Cabo live up to its potential? I guess we'll have to wait and see. But for now, the future looks bright for treating cancer, at least in my opinion.

Let me know what you think! Drop a comment,
AJ

No comments:

Post a Comment